Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Dutronc

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Immunology (Baltimore, Md. : 1950)|October 18, 2000
Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cellsB Bonish, D Jullien, Y Dutronc, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 4, 2016
Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studiesA B Gottlieb, J-P Lacour, N Korman, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 20, 2015
Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasisR G Langley, P Rich, A Menter, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 23, 2024
Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2M Senna, A Mostaghimi, M Ohyama, et al.
The British Journal of Dermatology|May 26, 2017
Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III studyK Reich, A Pinter, J P Lacour, et al.
The British Journal of Dermatology|January 24, 2020
The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trialsK W Wyrwich, H Kitchen, S Knight, et al.
The British Journal of Dermatology|March 13, 2020
Development of the Scalp Hair Assessment PRO™ measure for alopecia areataK W Wyrwich, H Kitchen, S Knight, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Immunology (Baltimore, Md. : 1950)|October 18, 2000
Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cellsB Bonish, D Jullien, Y Dutronc, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 4, 2016
Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studiesA B Gottlieb, J-P Lacour, N Korman, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 20, 2015
Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasisR G Langley, P Rich, A Menter, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 23, 2024
Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2M Senna, A Mostaghimi, M Ohyama, et al.
The British Journal of Dermatology|May 26, 2017
Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III studyK Reich, A Pinter, J P Lacour, et al.
The British Journal of Dermatology|January 24, 2020
The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trialsK W Wyrwich, H Kitchen, S Knight, et al.
The British Journal of Dermatology|March 13, 2020
Development of the Scalp Hair Assessment PRO™ measure for alopecia areataK W Wyrwich, H Kitchen, S Knight, et al.
Pageof 2